KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 20925 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Mind the gap: Bayesian equipoise calibration of clinical trial designs. PMID 42037202 · J Biopharm Stat · 2026-Apr-27 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Health-related quality of life with pertuzumab retreatment: Secondary analysis of the PRECIOUS trial. PMID 42061030 · Breast · 2026-Apr-26 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
How to design a ROCI (Response Over Continuous Intervention) randomised trial: guidance and a case study. PMID 42050422 · BMC Med Res Methodol · 2026-Apr-25 The article is a methodological guide and protocol description for a new trial design (ROCI), using a case study (REFINE-Lung) to illustrate the design. It does not report results of a completed Phase III or II/III randomized trial with a drug intervention and a time-to-event efficacy endpoint. Therefore, it is excluded as a protocol-without-results.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
[Preliminary analysis of mFOLFOXIRI plus bevacizumab combined with cytoreductive surgery for resectable peritoneal metastases from colorectal cancer: a prospective,randomized phase II clinical trial]. PMID 42045712 · Zhonghua Wei Chang Wai Ke Za Zhi · 2026-Apr-25 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Geriatric Oncology multidomain intervention study to prevent Cognitive impairment among older Indian patients with cancer receiving chemotherapy: a multicentric randomised controlled trial (GOCog). PMID 42034980 · BMC Geriatr · 2026-Apr-25 The record is a protocol for a randomized trial, not a results report. The primary endpoint is cognition (FACT-Cog), not a time-to-event efficacy endpoint. The trial phase is not specified. The intervention is non-drug (exercise + cognitive training), though chemotherapy is part of the standard care context.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and safety of ketogenic diet in glioblastoma: an updated systematic review and meta-analysis. PMID 42032215 · Neurol Sci · 2026-Apr-25 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Clinical Applications of Liquid Biopsy in Colorectal Cancer: A Focus on Registered Clinical Trials. PMID 42194957 · Genes (Basel) · 2026-Apr-24 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
A Randomized, Double-Blind, Positive-Controlled Phase III Clinical Trial of an Anti-Rabies Monoclonal Antibody for Category III Rabies Exposure in Individuals Under 18 Years - China, 2021-2023. PMID 42170015 · China CDC Wkly · 2026-Apr-24 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Vilaprisan in the Treatment of Uterine Fibroids: Data from ASTEROID 5, a Phase 3 Multicenter Randomized Controlled Trial. PMID 42122978 · J Clin Med · 2026-Apr-24 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Clazakizumab in the treatment of chronic active antibody-mediated kidney transplant rejection: Results from the IMAGINE phase 3, randomized, double-blind, placebo-controlled study. PMID 42035994 · Am J Transplant · 2026-Apr-24 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Effect of Continuous Theta-Burst Stimulation on Postoperative Delirium in Older Patients Who Undergo Cardiac Surgery. PMID 42033441 · Neuromodulation · 2026-Apr-24 The study is a randomized trial in humans with a primary result, but it is not oncology, does not involve a drug intervention, and does not have a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib plus bevacizumab (PAOLA-1/ENGOT-ov25). PMID 42033030 · J Natl Cancer Inst · 2026-Apr-24 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Comparison of immunity-boosting regimens for COVID-19 upon initiation of immunosuppressive therapy (CIRCUIT): study protocol for a randomised, controlled clinical trial. PMID 42031476 · BMJ Open · 2026-Apr-24 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Nivolumab and ipilimumab combination treatment in patients with advanced intrahepatic cholangiocarcinoma and gallbladder cancer: Results from the phase II MoST-CIRCUIT trial. PMID 42029635 · Clin Cancer Res · 2026-Apr-24 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Efficacy and safety of semaglutide injection in Indian patients with type 2 diabetes mellitus inadequately controlled on metformin: a phase 3, randomized, active-controlled trial (SIZE-DM study). PMID 42026662 · Cardiovasc Diabetol Endocrinol Rep · 2026-Apr-24 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A multicenter, placebo-controlled clinical trial and preliminary experimental study exploring the efficacy of modified Banxia Xiexin Decoction in the treatment of advanced colorectal cancer. PMID 41619866 · J Ethnopharmacol · 2026-Apr-24 The record describes a randomized, placebo-controlled clinical trial in advanced colorectal cancer with time-to-event endpoints (PFS, OS). However, the provided metadata does not explicitly confirm the trial phase as Phase III/IIIb or Phase II/III. The deterministic review flagged 'phase3_evidence_unclear'. Without explicit phase information, the eligibility criterion cannot be fully established.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Weifuchun inhibits gastric cancer metastasis by inhibiting angiogenesis mediated by the miR-139-5p/CXCR4 axis. PMID 41577154 · J Ethnopharmacol · 2026-Apr-24 The study is a randomized trial with a drug intervention and reports a time-to-event efficacy endpoint (DFS) for gastric cancer. However, the phase of the trial (e.g., Phase III/IIIb or II/III) is not explicitly established in the provided title, abstract, metadata, or deterministic review signals. The deterministic review flagged 'phase3_evidence_unclear'. Therefore, the 'phase3_or_definitive' criterion cannot be confirmed, making the study ineligible under the strict criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
[Comparison of the efficacy and safety of 36 000 IU vs. 40 000 IU recombinant human erythropoietin for the treatment of cancer-related anemia: a multicenter, open-label, randomized controlled trial]. PMID 42086522 · Zhonghua Zhong Liu Za Zhi · 2026-Apr-23 The study is an oncology randomized trial with a drug intervention and reports overall survival, but the explicit trial phase is not provided in the metadata or abstract. The primary efficacy endpoint is a continuous measure (hemoglobin change), not a time-to-event endpoint. The time-to-event component (overall survival) is reported as a secondary endpoint with no statistically significant difference, but the absence of a primary/key secondary time-to-event endpoint (like OS or PFS) as the main focus for digitization makes it ineligible for this specific cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Chemoradiotherapy and transanal endoscopic surgery versus transanal endoscopic surgery alone in T1N0M0 rectal cancer: a multicenter, randomized, controlled, phase III clinical trial (TAUTEM-T1 study). PMID 42026347 · Int J Colorectal Dis · 2026-Apr-23 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type no_km 0 Figure · 0 Panel · risk not_applicable
Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk Outpatients. PMID 42019019 · N Engl J Med · 2026-Apr-23 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Three Low-Dose Antihypertensive Agents in a Single Pill after Intracerebral Hemorrhage. PMID 42019018 · N Engl J Med · 2026-Apr-23 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Transdermal Estradiol Patches in Locally Advanced Prostate Cancer. PMID 41880608 · N Engl J Med · 2026-Apr-23 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Efficacy of a Modular App-Based Pelvic Floor Muscle Training Program for Postoperative Continence Recovery After Radical Prostatectomy: A Multi-Center Randomized Controlled Trial (PELVINTENSE Study). PMID 42122130 · Cancers (Basel) · 2026-Apr-22 The study is an oncology randomized controlled trial reporting primary results, but it evaluates a non-drug intervention (app-based pelvic floor muscle training) and does not have a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.). The primary endpoint is continence at 90 days (a binary outcome), not a time-to-event measure.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Consolidative Camrelizumab Following Definitive Concurrent Chemoradiation Therapy With Involved-Field Irradiation in Locally Advanced Esophageal Squamous Cell Carcinoma: A Single-Arm Phase 2 Trial. PMID 42031221 · Int J Radiat Oncol Biol Phys · 2026-Apr-22 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Re: Kitamura H, Tsukamoto T, Kakehi Y, et al. Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial. Eur Urol. 2026. PMID 42025515 · Eur Urol · 2026-Apr-22 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Re: Kitamura H, Tsukamoto T, Kakehi Y, et al. Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-Grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.01.008. PMID 42025514 · Eur Urol · 2026-Apr-22 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Hybrid robot-assisted surgery versus conventional fully robotic surgery for colon cancer: study protocol for a multicenter, parallel-group, single-blind randomized controlled superiority trial. PMID 42021265 · BMC Surg · 2026-Apr-22 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Single-cell dissection of persistent tumor antigens in non-responders reveals opportunities for TAA-targeted vaccination after neoadjuvant therapy in esophageal squamous cell carcinoma. PMID 42019971 · J Immunother Cancer · 2026-Apr-22 The study is a randomized Phase III trial in oncology with a drug intervention and reports original results, but it does not report a primary or key secondary time-to-event efficacy endpoint (such as OS, PFS, DFS, etc.) in the provided abstract. The focus is on biomarker and single-cell analysis of treatment response, not clinical survival outcomes.
H L B
旧查询独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Efficacy and safety of monoclonal antibodies in the treatment of relapsing remitting multiple sclerosis: a systematic review. PMID 42018029 · J Neurol · 2026-Apr-22 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Ensitrelvir for the treatment of hospitalized adults with COVID-19: an international phase 3 randomized placebo-controlled trial. PMID 42017206 · Clin Infect Dis · 2026-Apr-22 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Venous thromboembolism and bleeding in cancer patients: role of inflammatory and cardiac biomarkers. PMID 41384379 · Eur Heart J · 2026-Apr-22 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Topical Glucocorticosteroids for Proactive Therapy of Acute Radiation-Induced Skin Injury in Head and Neck Cancer: A Systematic Review and Meta-Analysis with Trial Sequential Analysis. PMID 42072482 · Biomedicines · 2026-Apr-21 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Oral Gonadotropin-Releasing Hormone Antagonists for the Treatment of Endometriosis-Associated Pain: A Systematic Review and Meta-Analysis. PMID 42025872 · J Minim Invasive Gynecol · 2026-Apr-21 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Integrated Prognostic Score in Metastatic Castration-resistant Prostate Cancer Treated with Cabazitaxel - A CABASTY Post Hoc Analysis Validated by Two International Prospective Phase 3 Trials. PMID 42020286 · Eur Urol Oncol · 2026-Apr-21 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Safety and Efficacy of Tranexamic Acid in Urologic Surgery: Results from the International, Randomized, Placebo-Controlled POISE-3 Trial. PMID 42020258 · Eur Urol · 2026-Apr-21 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Re: Kitamura H, Tsukamoto T, Kakehi Y, et al. Active surveillance versus intravesical bacillus Calmette-Guérin for high-grade T1 bladder cancer with negative second transurethral resection: the randomized noninferiority phase 3 JCOG1019 trial. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.01.008. PMID 42020257 · Eur Urol · 2026-Apr-21 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
A diagnostic randomized controlled trial to validate novel dried blood spot (DBS) based technology for prognosis and screening of leukemia transcripts: study protocol. PMID 42015297 · Trials · 2026-Apr-21 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
NEO-HYPORT: does neoadjuvant radiotherapy improve breast cancer outcomes? An open label, randomised, parallel group, superiority trial to compare the disease-free survival following neoadjuvant versus adjuvant hypofractionated radiotherapy in breast cancer (NEO-HYPORT). PMID 42015277 · Trials · 2026-Apr-21 The record describes a protocol for a randomized trial comparing neoadjuvant vs adjuvant radiotherapy (a non-drug intervention). It is not a report of original trial results with a drug intervention and a primary/key secondary time-to-event efficacy endpoint from a Phase III/IIIb or Phase II/III randomized trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
ProHealth: a co-designed online home-based healthy eating and exercise programme for men with prostate cancer treated with androgen deprivation therapy - a study protocol for a feasibility and preliminary efficacy randomised controlled trial. PMID 42014146 · BMJ Open · 2026-Apr-21 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Reduced-fluence photodynamic therapy versus placebo for central serous chorioretinopathy (REPLAY trial): rationale and study protocol of a pivotal double-blind randomised controlled trial. PMID 42014145 · BMJ Open · 2026-Apr-21 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Correction: Efficacy and safety of VPM1002 and Immuvac in preventing tuberculosis: phase 3 randomised clinical trial (PreVenTB trial). PMID 42014130 · BMJ · 2026-Apr-21 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Early versus deferred immunotherapy in urothelial carcinoma: a review of evidence and post-progression survival. PMID 42012774 · Int Urol Nephrol · 2026-Apr-21 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Study protocol, increasing awareness and early detection in students at risk of gynaecological cancer: feasibility of an online educational and behaviour change intervention. PMID 42010640 · Pilot Feasibility Stud · 2026-Apr-21 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Tumor Debulking in Combination With Chemotherapy in Multiorgan Metastatic Colorectal Cancer: The ORCHESTRA Randomized Clinical Trial. PMID 41837962 · JAMA · 2026-Apr-21 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Gonadotropin-releasing hormone agonist plus aromatase inhibitor versus oral progestins for fertility-sparing treatment in early endometrial carcinoma and atypical hyperplasia: interim analysis of a prospective controlled trial. PMID 42330749 · Int J Gynecol Cancer · 2026-Apr-20 This is an interim report of a prospective randomized controlled trial in oncology (early endometrial carcinoma/atypical hyperplasia) with a drug-containing intervention (GnRH agonist + aromatase inhibitor vs. progestins). However, it is not a Phase III/IIIb or Phase II/III definitive trial (phase is not specified as such, and the interim nature suggests it may be a smaller or earlier-phase study). More critically, the primary endpoint is complete response rate (a binary outcome), not a pre-specified time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, or an endpoint reported via Kaplan-Meier/HR). Recurrence rates are mentioned but not as a primary/key secondary time-to-event endpoint with KM/HR. Therefore, it does not meet the core eligibility criteria for a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Metastatic Colorectal Cancer Beyond Third-Line Treatment: Systematic Review and Meta-Analysis of Later-Line Therapies. PMID 42074928 · J Clin Med · 2026-Apr-20 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Improved outcomes of the refined risk-stratification and risk-adapted therapy in children with acute myeloid leukemia: final results of the AIEOP AML 2013. PMID 42010655 · J Hematol Oncol · 2026-Apr-20 Eligibility criteria are met except for the explicit confirmation of a Phase III/IIIb or Phase II/III trial. The study is a randomized trial in human pediatric oncology with drug interventions and time-to-event endpoints (OS, EFS), presenting final comparative results. However, the phase is not explicitly declared in the provided information, and inference is not allowed per adjudication rules.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Reporting of dog-assisted intervention trials: extension of the SPIRIT 2025 and CONSORT 2025 statement. PMID 42010497 · BMC Med Res Methodol · 2026-Apr-20 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Long-term survival and cure fraction in patients with advanced hepatocellular carcinoma under immunotherapy in randomized controlled trials and real-world data. PMID 42008357 · Clin Cancer Res · 2026-Apr-20 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Suprapapillary stent-by-stent deployment using slim fully covered metal stents versus plastic stents for unresectable malignant hilar biliary obstruction (SBSFLUX Trial): protocol for a multicenter randomized controlled trial. PMID 42002818 · Trials · 2026-Apr-20 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -